Best of the Week
Most Popular
1.Gold Price Trend Forecast, Where are the Gold Traders? - Bob_Loukas
2.Stocks Bear Market of 2017 Begins? Shorting the Dow At its Peak! - Nadeem_Walayat
3.Betting on President Trump Leaving Office Early, Presidency End Date - Betfair Market - Nadeem_Walayat
4.Why Stock Market Analysts Will be Wrong About 2017 - Clif_Droke
5.Is This The Best Way For Investors To Play The Electric Car Boom - OilPrice_Com
6.Silver Price 2017 Trend Forecast Update - Video - Nadeem_Walayat
7.Gold Price Set For Very Bullish 2017, Trend Forecast - Austin_Galt
8.10 Things I learned From Meetings With Trump’s Transition Team - - John_Mauldin
9.How Investors Can Profit From Trumps Military Ambitions - OilPrice_Com
10.Channel 4 War on 'Fake News', Forgets Own Alt Reality Propaganda Broadcasting - Nadeem_Walayat
Last 7 days
Brent Crude Oil Price Technical Update: Low Volatility Leads to High Volatility - 20th Feb 17
Trump’s Tax System Could Spark The Wave Of Self-Employment - 20th Feb 17
Here’s How to Stay Ahead of Machines and AI - 20th Feb 17
Warning Signs Of Instability In Russia - 20th Feb 17
Warning: This Energy Investment Could Wreak Havoc On Your Portfolio - 20th Feb 17
The Mother of All Financial Bubbles will be Unimaginably Destructive when it Bursts - 19th Feb 17
Gold’s Fundamentals Strengthen - 18th Feb 17
The Flynn Fiascom, the Trump Revolution Ends in a Whimper - 18th Feb 17
Not Nearly Enough Economic Growth To Keep Growing - 18th Feb 17
SPX Stocks Bull Market Continues to make New Highs - 18th Feb 17
China Disaster to Trigger Gold Run, Trump to Appoint 5 of 7 Fed Governors - 18th Feb 17
Gold Stock Volume Divergence - 17th Feb 17
Gold, Silver, US Dollar Cycles - 17th Feb 17
Inflation Spikes in 2017, Supporting Gold Prices Despite Increased Odds of March Rate Hike - 17th Feb 17
Roses Are Red... and So's Been EURUSD's Trend - 17th Feb 17
Gold Trade Note Sighted - 17th Feb 17
Gold Is Undervalued Say Leading Fund Managers - 17th Feb 17
NSA, CIA, FBI, Media Establishment 'Deep State' War Against Emerging 'Trump State' - 16th Feb 17
Silver, Gold Stocks and Remembering the Genius of Hunter S. Thompson - 16th Feb 17
Maps That Show The US’ Strategy In Asia-Pacific - 15th Feb 17
The Trump Stock Market Rally Is Just Getting Started! - 15th Feb 17
Tesco Crisis - Fake Prices, Brexit Inflation Tsunami to Send Food Prices Soaring 10% 2017 - 15th Feb 17
Stock Market Indexes Appear Ready to Roll Over - 15th Feb 17
Gold Bull Market? Or was 2016 Just a Gold Bug Mirage? - 15th Feb 17
Here’s How Germany Buys Time From China - 15th Feb 17
The Stock Trader’s Actionable Guide to Trump - 15th Feb 17
Trump A New Jacksonian Era? The Fourth Turning (2) - 14th Feb 17
Stock Market Yet Another Wall Street 'Witch's Brew' - 14th Feb 17
This Is Why You Don’t Own A Lot Of Stocks - 14th Feb 17
Proposed Tax Reforms Face Enormous Headwinds - 14th Feb 17
BBC Inside Out Tesco Rip off Offers - Determined to Lose Big Spend Customers! - 13th Feb 17
Is the UK An Economy Built on Debt? - 13th Feb 17
Stock Market VIX Cycles set to Explode in March/April 2017 – Part 2 - 13th Feb 17
Stocks At Record Highs - Will Uptrend Accelerate? - 13th Feb 17
US Dollar: 'Rumors of My Death are Greatly Exaggerated' - 13th Feb 17
Is This The Top Commodity Play For 2017? - 13th Feb 17
Trump a New Jacksonian Era? - 13th Feb 17
Stock Market at High Tide - 13th Feb 17
Channel 4 War on 'Fake News' Ends - The New News Age - 12th Feb 17

Market Oracle FREE Newsletter

State of Global Markets 2017 - Report

Trump’s FDA Chief May Implement Progressive Approval for Drugs

Companies / Healthcare Sector Dec 20, 2016 - 07:35 AM GMT

By: John_Mauldin

Companies

BY PATRICK COX : President-elect Trump's cabinet appointments are generating a great deal of attention and controversy. After eight years of Democrat rule, it would be foolish to expect otherwise.

One appointment, though, will have a profound impact on your health… and the health of your loved ones.


The “progressive approval” process for drugs

The first potential FDA chief appointee leaked by the Trump transition team is Jim O’Neill. Managing director of Peter Thiel’s Mithril Capital, O’Neill has publicly supported proposals to do away with the FDA’s requirement for phase 2 and 3 trials. Instead, he favors “progressive approval” of drugs and other medical technologies.

O’Neill would not be the first FDA head to favor progressive drug approval. Andrew von Eschenbach developed this system when he served as FDA chief. But during his tenure, Eschenbach was not able to put such a far-reaching reform into practice in the US.

The Japanese, though, saw the value of Eschenbach’s plan. They now use it for regenerative medicine. Japan legalizes therapies following proof of safety. Once a drug is in use, companies can move to phase 4. This means they monitor their patients and disclose efficacy data regularly.

If O’Neill gets the nod, he could implement progressive approval for drugs. But he would face fierce opposition from those who profit from the current system.

The current drug approval system is flawed

Big pharma benefits a great deal from the status quo. Since many small biotechs can’t fund most phase 2 or 3 trials, they give up significant ownership of their biotechnologies to these giants in exchange for financial help.

Many other organizations are also paid billions each year for services related to phase 2 and 3 clinical trials. They too will argue that doing away with those trials would endanger patients.

Since therapies would have to be proven safe before reaching the public, they will charge that patients will be at risk from using treatments that don’t work.

This, of course, is true. But it’s also true that patients are put at risk because they are denied access to unapproved but effective drugs.

Also, we pay much more for available drugs because companies must recoup costs imposed by the regulatory system. How big are those costs? Estimates of the average cost of one new medicine range from $1 to $4 billion.

Another side effect of the current system is that many drugs never leave the lab. These are drugs that could effectively treat serious illness but aren’t worth the cost of approval. This is because the patient population is too small to recoup approval costs.

The FDA has made efforts to help to help biotechs develop orphan drugs, but these steps have not been enough to make much of an impact.

Genomics and the need for a new regulatory process

Genomics has changed the way we treat illness. As the cost of genome sequencing falls, the ability to design drugs that work in small populations with specific genetic characteristics is rapidly increasing.

Eric Topol is the Director of the Scripps Translational Science Institute. He suggests that randomized clinical trials for this kind of indication are not just impractical, they’re unethical. InSilico Medicine’s Alex Zhavoronkov is one of the leading researchers in genomics-based personalized medicine. He believes we will be able to design and manufacture drugs for a single genome.

But how do you do a blinded controlled trial for a drug that may work on just one person?

This is not just an issue for the future. Many life-saving breakthroughs that could save millions of lives and reduce medical costs are stalled right now. Two of the most important areas of research are geroprotectors and induced tissue regeneration (ITR).

Geroprotectors are compounds that repair the systems that accelerate aging and age-related disease. Major universities and research organizations have found at least half a dozen molecules that could slow aging and extend health spans… even in older people.

Why haven’t you seen these compounds? Because phase 2 and 3 trials would take a decade or more… while increasing their prices by orders of magnitude.

Induced Tissue Regeneration (ITR) has even greater potential. ITR is an emerging technology that could reactivate the embryonic healing powers hidden deep in your DNA. It could restore lost limbs, broken spinal cords, or any other body part to youthful function. Eyes, hearts, joints, skin, and livers could be taken back in time using relatively simple compounds.

If it weren’t for the fact that Dr. Michael West is spearheading this new field, I would dismiss it as a pipe dream. West’s spinal cord stem cell therapy recently saved complete quadriplegics from a life of total dependency. Almost no one thought that he could do this. In fact, I got emails saying that the trial would fail, and this was after the first patient got back to ability to lift weights, text, and care for himself.

The important thing to note about this therapy is how long it took to get approved. West invented it over 20 years ago. It took that long to drag this miraculous biotechnology through the regulatory maze.

The big picture for ITR

Over the past 20 years, the pace of West's research and scientific progress has accelerated along with breakthroughs in computers and genomics. Now, he is on the verge of activating in adults the same genetic power evident in developing embryos. 

For years, I’ve gleaned what I could about this project by following West’s public statements and patent applications. Finally, he’s begun to tell the whole revolutionary story. Following the success of spinal cord technology, he laid out the big ITR picture in a keynote address to the prestigious World Stem Cell Summit.

ITR may be the biggest breakthrough in the history of medicine. The ability to make old and damaged organs and tissues young again will change countless lives. For millions of older people, though, it will come too late unless the regulatory bureaucracy is transformed to accelerate life-saving therapies.

Maybe Jim O’Neill will be the person to make it happen.

In the interest of transparency, I should note that I own stock in Michael West’s company BioTime (*see disclosure below).

Stay in the Loop on Life-Extending Research with Patrick Cox's Tech Digest

This weekly newsletter by biotech expert Patrick Cox highlights research that is much more advanced than most people know, and the profit potential for investors is vast. Read about the latest breakthroughs—from new, non-invasive cancer treatments to age-reversing nutraceuticals and vaccines that kill any virus–as well as the innovative companies that work on them. Get Tech Digest free in your inbox every Monday.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

John Mauldin Archive

© 2005-2016 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife